WeTrials
Recruiting

Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor

What is this study?

This study is testing if adding a targeted medication called a CDK4/6 inhibitor to the hormone-blocking drug elacestrant works better than elacestrant alone. It aims to help patients with a common type of advanced breast cancer who have already tried similar treatments.

Who can participate?

You may be able to join if you have ER-positive, HER2-negative advanced breast cancer with a specific gene mutation called ESR1, and you have previously received hormone therapy that included a CDK4/6 inhibitor.

What will happen?

Participants will be randomly placed into one of two groups to receive either elacestrant by itself or elacestrant combined with a CDK4/6 inhibitor. Your health and the cancer's response will be closely monitored through regular scans and check-ups.

Where and when?

The study is currently recruiting participants and takes place in Chicago, Illinois, United States.

Key Points
  • 1Tests a combination of hormone-blocking and targeted medications
  • 2For advanced breast cancer patients who have already tried specific prior therapies
  • 3Currently recruiting participants in Chicago, Illinois

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Estrogen-receptor-positive Breast CancerHER2/Neu-Negative Breast CancerAdvanced Breast CancervMetastatic Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.